Article Text

Download PDFPDF

010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort
  1. Helmut Butzkueven1,2,
  2. Tim Spelman2,
  3. Tomas Kalincik3,
  4. Katherine Buzzard4,
  5. Anneke Van der Walt1,
  6. Jeanette Lechner-Scott5,
  7. Suzanne Hodgkinson6,
  8. Ernest Butler7,
  9. Richard Macdonell8,
  10. Mark Slee9,
  11. MSBase Study Group2 and
  12. Bruno Marcel10
  1. 1Monash University, Melbourne, VIC, Australia
  2. 2MSBase Foundation, Melbourne, VIC, Australia
  3. 3University of Melbourne, Melbourne, VIC, Australia
  4. 4Box Hill Hospital, Box Hill, VIC, Australia
  5. 5University of Newcastle, Newcastle, NSW, Australia
  6. 6Liverpool Hospital, Sydney, NSW, Australia
  7. 7Monash Medical Centre, Melbourne, VIC, Australia
  8. 8Austin Health, Melbourne, VIC, Australia
  9. 9Flinders University, Adelaide, SA, Australia
  10. 10Roche Products Pty Ltd, Sydney, NSW, Australia


Introduction Ocrelizumab (OCR) is a humanised anti-CD20+ monoclonal antibody for the treatment of Multiple Sclerosis.

Objectives In Australian MSBase clinics, we describe baseline characteristics of relapsing-remitting MS (RRMS) patients treated with OCR, treatment pathways and early clinical outcomes.

Methods Secondary analysis using MSBase Registry data for RRMS patients with OCR initiation within 3 months of MSBase recorded visit. Descriptive statistics included demographics, disease course/duration, prior disease modifying therapies (DMT) and EDSS. Relapse data was described in patients with ≥6 months follow-up.

Results As of 4 June 2020, MSBase included 624 eligible Australian RRMS patients newly treated with OCR. Median age at OCR initiation was 42.5 years. OCR was first line therapy in 18.9% of patients. Most frequent DMT’s in the 12 months prior to OCR were natalizumab (32.1%) and fingolimod (24.8%). Of 434 RRMS patients with ≥6 months follow-up, 392 remained relapse free (90.3%; 95% CI 81.6, 99.7) over a mean OCR exposure of 1.35 years. In this group, the annualized relapse rate (ARR) was 0.10 (95% CI 0.08-0.13), compared to an ARR of 0.83 in the 24 months pre-OCR start. Treatment discontinuation was recorded for 20 of these 434 patients In the overall RRMS cohort, treatment persistence at 12 and 24 months was 94.3% (95%CI: 90.9%-96.1%%) and 88.7% (95%CI 77.2%-94.0%), respectively.

Conclusion Almost 20% of RRMS patients treated with OCR in Australian MSBase centres received OCR as a first line treatment. During OCR treatment, relapses and OCR discontinuations were rare.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.